Skip to main content
Fig. 3 | Lipids in Health and Disease

Fig. 3

From: Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials

Fig. 3

Subgroup analyses sorted by treatment dose and duration. a and b LSM changes of LDL-C and HDL-C levels across placebo, baricitinib 2 mg and 4 mg from week 12 to week 24 to baseline. Values presented as LSM ± SE. vs. placebo, *** p < 0.001; c Subgroup analysis of LDL-C changescores; d Subgroup analysis of HDL-C change scores. Notes, Bari, baricitinib; WMD, weighted mean difference; LSM, least squares mean. SE, standard error

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X